NCT06416995View on ClinicalTrials.gov

Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes

RecruitingOBSERVATIONAL
Enrollment

88

Participants

Timeline

Start Date

March 3, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

December 30, 2024

Conditions
PreeclampsiaGestational HypertensionGestational DiabetesPreterm BirthFetal Growth Retardation
Interventions
DIAGNOSTIC_TEST

first trimester serum diagnostic test

First trimester serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations predict adverse perinatal outcomes

Trial Locations (1)

34764

RECRUITING

Ümraniye Eğitim ve Araştırma Hastanesi, Istanbul

All Listed Sponsors
lead

Umraniye Education and Research Hospital

OTHER_GOV